glp-1/gip/glucagon receptor agonist Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Frontiers | Striking the Balance:

Shared decision-making should take place, considering their current health status

Some researchers have highlighted post-treatment study findings that have shown that people tend to suffer from a high risk of weight regain after stopping these drugs

Their benefits now extend well beyond glycemic control and weight loss, with growing evidence supporting their use in the management of steatosis liver disease, obstructive sleep apnea, cardiovascular disease, and chronic kidney disease

The In-Competition period starts at 11:59 pm on the day before the competition through to the end of the competition and the sample collection process related to the competition

Recently, to ensure the safety of GLP-1 RA on sarcopenia, a clinical randomized multicenter trial of bimagrumab, an antibody blockade of activin type II receptor inhibitor, alone or in addition to subcutaneous semaglutide is now ongoing (NCT05616013) [113]